First US Postpartum Depression Medication Is Approved By The FDA
The drug zuranolone has been given the green light by the US Food and Drug Administration to be used in the treatment of postpartum depression. This makes it the first oral medication in the country to be approved by the FDA specifically for the condition, which affects 1 in 7 new mothers after giving birth. The FDA declared on Friday that the medication, to be marketed under the trade name Zurzuvae, had been authorised as a once-daily dose taken over a period of 14 days. “ Postpartum depression is a serious and even fatal disorder in which women experience grief, remorse, and a sense of worthlessness, and in extreme cases, even suicidal thoughts. Postpartum depression may also affect the child’s physical and emotional development since it can damage the mother-infant attachment, according to Dr. Tiffany R. Farchione, director of the Division of Psychiatry of the FDA’s Centre for Drug Evaluation and Research. For many of these women who are suffering with intense, and occasionall...